<DOC>
	<DOCNO>NCT00907959</DOCNO>
	<brief_summary>The investigator ' propose phase 2 clinical trial open-label , non-randomized study among 80 woman metastatic breast cancer . The study treatment period twelve month enrollment open 10-15 clinical site United States . In Phase 2 trial , 40 participant hormone receptor positive tumor 40 hormone receptor negative tumor enrol treated BZL101 20 grams/day ( 10 gram BID ) . Hormone receptor positive define estrogen receptor ( ER ) + progesterone receptor ( PR ) + , ER+ PR- , ER- PR+ . Hormone receptor negative define ER- PR- .</brief_summary>
	<brief_title>A Clinical Trial Assessing Safety Efficacy BZL101 Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Women 18 year old . 2 . Histologically confirm diagnosis breast cancer base pathology report primary , regional metastatic breast cancer . 3 . Clinical evidence metastatic ( stage IV ) involvement bone metastasis base investigator 's clinical and/or radiographic finding . 4 . Availability estrogen receptor progesterone receptor status measure biopsy tissue . ( Status recent biopsy ER/PR status document used determine hormone receptor status stratification ) . 5 . At least one measurable disease site define RECIST criterion , measurement make within 30 day begin study therapy . ( Nonmeasurable disease include bone lesion , leptomeningeal disease , ascites , pleural/pericardial effusion , inflammatory breast disease , lymphangitis cutis/pulmonis , abdominal mass confirm followed imaging technique , cystic lesion . For lesion previously irradiate field , radiate lesion assess measurable lesion unless growth lesion document radiation ) . 6 . No 2 prior cytotoxic regimen administer metastatic breast cancer . ( Participants may receive number exogenous hormone therapy Stage IV disease and/or adjuvant therapy ) . 7 . Life expectancy &gt; 12 week . 8 . Eastern Cooperative Oncology Group performance status &lt; 2 . 9 . Women child bear potential must agree use two adequate method contraception abstain sexual intercourse study treatment . Acceptable method contraception follow : 1 . Intrauterine device ( IUD ) 2 . Hormonal birth control 3 . Tubal ligation 4 . Partner 's vasectomy 5 . Latex condom 6 . Diaphragm 7 . Cervical cap 10 . Adequate organ marrow function measure within 14 day study treatment define : Absolute neutrophil count &gt; 1,500 cells/mm3 Platelets &gt; 100,000 cells/mm3 Hemoglobin &gt; 10 g/dL Total bilirubin &lt; 1.5 mg/dL AST ( SGOT ) /ALT ( SGPT ) &lt; 2.5 X institutional upper limit normal &lt; 5 X normal document liver metastasis Alkaline Phosphatase &lt; 3 X institutional upper limit normal &lt; 5 X normal document liver bone metastasis Serum creatinine &lt; 1.5 mg/dL Creatinine clearance &gt; 60 mL/min/1.73 m2 participant serum creatinine level institutional normal .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>